SubHero Banner

Trodelvy® (sacituzumab govitecan-hziy) – New indication

April 13, 2021 - Gilead Sciences announced the FDA approval of Trodelvy (sacituzumab govitecan-hziy), for the treatment of locally advanced or metastatic urothelial cancer (UC) in adult patients who have previously received platinum-containing chemotherapy and either a programmed death receptor-1 (PD-1) or a programmed death-ligand 1 (PD-L1) inhibitor. 

Download PDF